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Abstract
Introduction Increasing numbers of cancer patients are being
admitted to the intensive care unit (ICU), either for cancer-
related complications or treatment-associated side effects, yet
there are relatively few data concerning the epidemiology and
prognosis of cancer patients admitted to general ICUs. The aim
of this study was to assess the characteristics of critically ill
cancer patients, and to evaluate their prognosis.
Methods This was a substudy of the Sepsis Occurrence in
Acutely Ill Patients (SOAP) study, a cohort, multicentre,
observational study that included data from all adult patients
admitted to one of 198 participating ICUs from 24 European
countries during the study period. Patients were followed up
until death, hospital discharge or for 60 days.
Results Of the 3147 patients enrolled in the SOAP study, 473
(15%) had a malignancy, 404 (85%) had solid tumours and 69
(15%) had haematological cancer. Patients with solid cancers
had the same severity of illness as the non-cancer population,
but were older, more likely to be a surgical admission and had a
higher frequency of sepsis. Patients with haematological cancer
were more severely ill and more commonly had sepsis, acute
lung injury/acute respiratory distress syndrome, and renal failure
than patients with other malignancies; these patients also had
the highest hospital mortality rate (58%). The outcome of all
cancer patients was comparable with that in the non-cancer
population, with a 27% hospital mortality rate. However, in the
subset of patients with more than three failing organs, more than
75% of patients with cancer died compared with about 50% of
patients without cancer (p = 0.01).
Conclusions In this large European study, patients with cancer
were more often admitted to the ICU for sepsis and respiratory
complications than other ICU patients. Overall, the outcome of
patients with solid cancer was similar to that of ICU patients
without cancer, whereas patients with haematological cancer
had a worse outcome.
Introduction
Remarkable advances have been made in the early diagnosis
and aggressive management of patients with malignancies,
resulting in dramatic improvements in overall survival rates
[1,2]. As a result, increasing numbers of patients are admitted
to the intensive care unit (ICU), either for cancer-related com-
plications or for treatment-associated side effects [3]. Several
studies have reported very high mortality rates for cancer
patients after a long ICU stay, especially when they had leuco-
penia [4] or required mechanical ventilation [5], and aggres-
sive management of life-threatening complications in these
patients has been questioned [6]. In a prospective, longitudi-
nal study performed in 26 ICUs, Azoulay and colleagues found
that cancer patients were at a high risk of being denied ICU
admission [7], in accordance with articles discouraging ICU
admission or prolonged intensive care for cancer patients
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[6,8]. However, other studies have highlighted reduced mor-
tality rates in critically ill patients with cancer [9,10], and the
development of new procedures, such as non-invasive
mechanical ventilation, may enable recommendations for ICU
admission and appropriate utilisation of ICU resources for can-
cer patients to be altered [11].
Several large epidemiological studies have provided findings
on prognostic factors for cancer patients admitted to the ICU
[1,12,13], but these studies essentially concerned specialised
oncological ICUs, so extrapolation to general ICUs and hospi-
tals can be difficult. There are several issues of particular inter-
est. First, it is important to determine if mortality rates are
different for patients with and without cancer in a general ICU.
In particular, because sequential assessment of organ failure
is fundamental to predict outcome in the general ICU popula-
tion [14], it would be interesting to know whether the relation-
ship between the number of acute organ failures and mortality
is different in patients with and without malignancy. Second,
sepsis remains one of the major causes of admission for can-
cer patients to the ICU and is an important cause of hospital
mortality and morbidity [15]. Moreover, treatment of cancer
has contributed to a growing number of immunocompromised
patients with an increased incidence of nosocomial infections
[16]; immunosuppression can result in a greater use of antibi-
otics and more infections associated with multiresistant micro-
organisms [17]. It is, therefore, also important to define
whether cancer patients have more sepsis episodes and sep-
sis-related organ dysfunctions than non-cancer patients.
The Sepsis Occurrence in Acutely Ill Patients (SOAP) study
[15] collected a large amount of data on all patients admitted
to general (non-specialised) ICUs during a two-week period.
As there are relatively few data concerning the epidemiology
and prognosis of cancer patients admitted to general ICUs or
the epidemiology and patterns of sepsis syndromes in these
patients [17,18], the aim of this study was to assess the char-
acteristics of critically ill cancer patients, and to evaluate their
prognosis.
Materials and methods
Study design
This study was a substudy of the prospective, multi-centre,
observational SOAP study. The SOAP study [15] was
designed to evaluate the epidemiology of sepsis and to iden-
tify various aetiological, diagnostic, therapeutic and prognostic
factors of ICU patients in European countries, and was
endorsed by the European Society of Intensive Care Medicine.
Although this observational study did not require any deviation
from routine medical practice, institutional review board
approval was either waived or expedited in participating insti-
tutions and informed consent was not required. As such, no
supplementary review board documents were needed for the
current sub-study.
All patients older than 15 years that were newly admitted to
the ICU of a participating centre (see the list of participating
countries and centres in Additional File 1) between 1 and 15
May, 2002, were included in the study. Patients were followed
up until death, hospital discharge or for 60 days, whichever
came first. Those who stayed in the ICU for longer than 24
hours for routine postoperative observation were excluded.
Patients who were readmitted and had been included on their
first admission were not included for a second time.
Definitions
Details of all the definitions used in the SOAP study have been
published previously [15]. Infection was defined as the pres-
ence of a pathogenic micro-organism in a sterile site (such as
blood, abscess fluid, cerebrospinal fluid or ascites) and/or
clinically suspected infection, plus the administration of antibi-
otics. Sepsis was defined according to standard criteria [19].
ICU-acquired sepsis was defined as sepsis occurring more
than 48 hours after admission to the ICU. Patients were
defined as having acute lung injury (ALI) or acute respiratory
distress syndrome (ARDS) if the arterial oxygen pressure to
inspiratory oxygen fraction ratio (PaO2/FiO2) was less than
300 for ALI and less than 200 for ARDS and all of the follow-
ing were present: bilateral infiltrates on the chest radiograph;
no clinical evidence of heart failure; no chronic pulmonary dis-
orders; and mechanical ventilation. Organ failure was defined
as a Sequential Organ Failure Assessment (SOFA) score
more than 2 for the organ in question [20]. Patients were clas-
sified as surgical admissions if they had undergone surgery
within two weeks preceding admission.
Cancer was identified as solid or haematological malignancy
diagnosed before admission to the ICU. For solid tumours, the
presence of metastases was also recorded. Patients with a
prior history of cancer and with complete remission for over
five years were not considered in the cancer group. Leucope-
nia was defined as a white blood cell count less than 1000
cells/mm3, and severe thrombocytopenia by a platelet count
less than 50,000 cells/mm3 [19].
Data management
Data were collected prospectively using pre-printed case
report forms filled in following instructions available on a dedi-
cated website. The steering committee was easily accessible
to the investigators and processed all queries during data col-
lection. Data collection on admission included demographic
data and comorbid diseases. Clinical and laboratory data for
the Simplified Acute Physiology Score (SAPS) II [21] were
reported as the worst value within 24 hours after admission.
Microbiological and clinical infectious data were reported daily
as well as the antibiotics administered. A daily evaluation of
organ function based on the SOFA score [14] was performed,
with the most abnormal value for each of six organ systems
(respiratory, renal, cardiovascular, hepatic, coagulation and
neurological) being collected on admission and every 24Available online http://ccforum.com/content/13/1/R15
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hours thereafter. Data collection and quality control are
described elsewhere [15].
Statistical analysis
Data were analysed using SPSS 13.0 for Windows (SPSS
Inc., Chicago, IL, USA). Descriptive statistics were computed
for all study variables. A Kolmogorov-Smirnov test was used,
and histograms and normal-quantile plots were examined to
verify the normality of distribution of continuous variables. Dis-
crete variables are expressed as counts (percentage) and con-
tinuous variables as means ± standard deviation (SD) or
median (25th to 75th percentiles). For demographics and clin-
ical characteristics of the study groups, differences between
groups were assessed using a chi-square, Fisher's exact test,
Student's t-test or Mann-Whitney U test, as appropriate.
Multivariate logistic regression analysis with hospital mortality
as the dependent variable was conducted in patients with
solid and haematological cancer. Only variables associated
with a higher risk of hospital mortality (p < 0.25) on a univariate
basis were introduced in the multivariate model. Colinearity
between variables was excluded prior to modelling. A Hosmer-
Lemeshow goodness-of-fit test was performed and
Nagelkerke pseudo r2, classification tables, and odds ratios
(OR) with 95% confidence interval (CI) were computed. Vari-
ables considered in the analysis were, therefore, demographic
variables, co-morbidities, SAPS II score on admission, organ
failure as assessed by the SOFA score on admission, pres-
ence of metastases, type of admission (medical or surgical),
reason for admission, sepsis, source of infection, type of
micro-organism (Pseudomonas aeruginosa, methicillin-resist-
ant Staphylococcus aureus, Escherichia coli, Candida spe-
cies) following results of descriptive data on infection
incidence, mechanical ventilation, renal replacement therapy
(haemofiltration or haemodialysis), administration of inotropes
and/or vasopressor agents, presence of leucopenia, thrombo-
cytopenia, ALI or ARDS. Kaplan-Meier survival curves were
plotted and compared using a signed log-rank test. All statis-
tics were two-tailed and a p < 0.05 was considered signifi-
cant.
Results
Demography
From 3,147 patients enrolled during the study period, 473
(15%) had a malignancy. Of these, 69 (15%) had haematolog-
ical cancer and 404 (85%) had solid tumours, of whom 100
had evidence of metastases. The patients with solid tumours
were older than the patients without cancer and were more
commonly male (Table 1). Surgical admissions accounted for
almost 70% of the patients with solid cancer compared with
41% of those without cancer, and 20% of those with haema-
tological cancer (Table 1). Gastrointestinal, thoracic, and
renal/urological surgery were more common, and cardiovascu-
lar and neurosurgery less common, in patients with solid
tumours than in those without cancer. Cancer patients were
more commonly admitted for respiratory reasons, but less
commonly for acute neurological diseases and trauma. SAPS
II and SOFA scores were comparable in patients with solid
tumours and those without cancer, but both scores were sig-
nificantly higher in patients with haematological cancer than in
those without cancer. The median lengths of stay in the ICU
were quite similar in the three groups, but cancer patients had
longer hospital stays than those without cancer. Co-morbidi-
ties were different among the groups, with a lower prevalence
of cardiac insufficiency in patients with solid tumours, and
more patients with AIDS in patients with haematological can-
cer. Corticosteroids and chemotherapy were more commonly
used in patients with cancer than in those without.
Frequency, distribution and patterns of sepsis
Of 1,177 (37% of the total population) patients with identified
infection, 217 (18%) had cancer (Table 1). More patients with
haematological cancer had severe sepsis and septic shock
than patients without cancer, already on admission. There was
no difference in the rate of ICU-acquired infections among the
three groups. The most common site of infection in all three
groups, both at admission and during the ICU stay, was the
lung (Table 2). Abdominal infections occurred more frequently
in patients with solid cancer compared with patients without
cancer. Patients with haematological cancer had more epi-
sodes of bacteraemia than patients without cancer. The most
common micro-organisms are presented in Table 2. E. coli
was more frequently isolated in cancer patients than in
patients without cancer. There was no significant difference in
the micro-organisms recovered from blood cultures (data not
shown).
Organ dysfunction
Renal (29% versus 37%, p = 0.01) and neurological (20%
versus 26%, p = 0.02) dysfunction were less common in
patients with solid tumours than in those without cancer, and
these differences were already present at admission. Patients
with haematological cancer more commonly had respiratory
(55% versus 40%, p = 0.01), circulatory (50% versus 32%, p
= 0.001), and especially coagulation (45% versus 8%, p <
0.001) dysfunction during the ICU stay than patients without
cancer. As expected, leucopenia was more common in
patients with solid tumours and in patients with haematologi-
cal cancer (Table 3). Patients with haematological cancer had
lower PaO2/FiO2 ratios and a higher incidence of ALI/ARDS
than patients without cancer. There were no differences in the
number of failing organs per day (median 2.0 (interquartile
range 1.0 to 3.0)) for the three groups; however, the mean
number of organ failures was higher in patients with haemato-
logical cancer than in patients without cancer (p = 0.02). Fig-
ure 1 shows the number of organs failing and the
corresponding mortality. Hospital mortality increased with the
number of organs failing, especially in cancer patients when
more than three organs failed (121 of 241 (50%) non-cancerCritical Care    Vol 13 No 1    Taccone et al.
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Table 1
Demographic characteristics of patients
No cancer
(n = 2674)
Solid tumours
(n = 404)
Haematological cancers
(n = 69)
Age, years 59.6 ± 17.9 66.4 ± 12.1$ 62.1 ± 15.9
Malea 1619 (61.2%) 265 (66.6%)* 36 (52.9%)
Type of admission
Medical 1581 (59.1%) 123 (30.4%)$ 55 (79.7%)*
Surgical 1093 (40.9%) 281 (69.6%)$ 14 (20.3%)*
Neurosurgery 131 (11.9%) 20 (7.1%)* 1 (7.1%)
Digestive surgery 284 (26.0%) 174 (61.9%)$ 7 (50%)
Thoracic surgery 28 (2.5%) 24 (8.5%)$ 2 (14.2%)
Cardiovascular surgery 453 (41.4%) 13 (4.6%)$ 3 (21.4%)
Renal/urological surgery 25 (2.3%) 22 (7.8%)$ 0
Other surgery 136 (12.4%) 23 (8.2%)* 1 (7.1%)
Admission source
Hospital floor 639 (26.4%) 118 (33.1%)* 36 (61.0%)$
ER/ambulance 849 (35.1%) 56 (15.7%)$ 8 (13.6%)$
Recovery room 623 (25.7%) 152 (42.7%)$ 9 (15.3%)
Other hospital 309 (12.8%) 30 (8.4%)* 6 (10.2%)
Reason for admission
Surveillance 192 (7.6%) 54 (14.8%)$ 1 (1.4%)
Digestive/liver 236 (9.3%) 88 (24.1%)$ 9 (13.0%)
Respiratory 432 (17.0%) 96 (26.3%)$ 32 (46.4%)$
Cardiovascular 874 (34.5%) 56 (15.3%)$ 19 (27.5%)
Haematological 24 (0.9%) 3 (0.8%) 0
Neurological 446 (17.6%) 36 (9.9%)$ 3 (4.3%)*
Renal 81 (3.2%) 19 (5.2%) 4 (5.8%)
Metabolic 60 (2.4%) 10 (2.7%) 1 (1.4%)
Trauma 179 (7.1%) 2 (0.5%)$ 0*
Comorbidities and therapies on admission
COPD 292 (10.9%) 42 (10.4%) 6 (8.7%)
Diabetes 200 (7.5%) 24 (5.9%) 2 (2.9%)
Liver cirrhosis 103 (3.9%) 18 (4.5%) 0
AIDS 12 (0.4%) 3 (0.7%) 3 (4.3%)*
Heart failure 276 (10.3%) 22 (5.4%)* 9 (13%)
Corticosteroids 123 (4.6%) 28 (6.9%)* 14 (20.3%)$
Chemotherapy 8 (0.3%) 10 (2.5%)$ 7 (10.1%)$
SAPS II 36.0 ± 16.8 36.8 ± 17.6 53.5 ± 18.5$
Incidence of sepsis
Sepsis 960 (35.9%) 168 (41.5%)$ 49 (71%)$
Severe sepsis 780 (29.1%) 110 (27.2%) 40 (57.9%)$
Septic shock 380 (14.3%) 57 (14.1%) 23 (33.3%)$
Sepsis on admission 634 (23.7%) 107 (26.5%) 36 (52.2%)$
ICU-acquired sepsis 228 (8.5%) 43 (10.6%) 8 (11.6%)
Severe sepsis on admission 462 (17.3%) 64 (15.8%) 26 (37.7%)$
Septic shock on admission 197 (7.4%) 31 (7.7%) 15 (21.7%)$
Admission SOFA 5.2 ± 3.8 4.6 ± 3.6 7.0 ± 4.6*
ICU stay, days 3.0 (1.7 to 7.0) 3.0 (1.8 to 6.4) 3.8 (1.7 to 8.6)
Hospital stay, days 14.0 (7.0 to 31.0) 20.0 (12.0 to 33.0)* 22.5 (10.0 to 38.0)*
COPD = chronic obstructive pulmonary disease; ER = emergency room; ICU = intensive care unit; SAPS = simplified acute physiology score; 
SOFA = sequential organ failure assessment. Data are presented as mean ± standard deviation, number (percentage), or median (interquartile 
range).
* p < 0.05 versus no-cancer group; $ p < 0.001 versus no-cancer group; a 35 missing valuesAvailable online http://ccforum.com/content/13/1/R15
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patients versus 29 of 37 (78%) patients with cancer; p =
0.01).
Monitoring and therapy
Arterial catheters were more commonly used in patients with
haematological cancer, but pulmonary artery catheters were
less commonly used in patients with solid tumours (Table 3),
and this difference was not explained by the type of surgery
(cardiac surgery in particular) or the frequency of heart failure
in a multivariable analysis (data not shown).
Mechanical ventilation was used in more than 60% of patients
with similar median duration. Patients with haematological
cancer were more often treated with haemofiltration, vaso-
pressors and inotropes.
Table 2
Characteristics of infected patients according to the type of malignancy
No cancer
(n = 960)
Solid tumours
(n = 168)
Haematological cancer
(n = 49)
Criteria for infection
Clinically suspected 750 (78.1%) 136 (81%) 38 (77.6%)
Microbiologically confirmed 666 (69.4%) 114 (67.9%) 34 (69.5%)
Clinical signs and micro-organism 383 (39.9%) 71 (42.5%) 14 (28.6%)
Source of infection
Respiratory 648 (67.5%) 108 (64.3%) 38 (77.6%)
Abdominal 200 (20.8%) 56 (33.3%)$ 7 (14.3%)
Blood stream 196 (20.4%) 26 (15.5%) 16 (32.7)*
Skin 132 (13.8%) 23 (13.7%) 3 (6.1%)
Urinary 133 (13.9%) 22 (13.1%) 4 (8.2%)
Catheter 87 (9.1%) 18 (10.7%) 6 (12.2%)
Cerebrospinal fluid 15 (1.6%) 0 (0.0%) 0 (0.0%)
Unknown 53 (5.5%) 7 (4.1%) 3 (6.1%)
Gram-positive bacteria
Streptococcus group D 97 (10.1%) 21 (12.5%) 5 (10.2%)
Streptococcus pneumoniae 42 (4.3%) 3 (1.7%) 1 (2.0%)
MRSA 131 (13.6%) 28 (16.6%) 5 (10.2%)
Other cocci 20 (2.1%) 3 (1.8%) 0
Gram-negative bacteria
Pseudomonas 132 (13.7%) 21 (12.5%) 10 (20.4%)
Escherichia coli 114 (11.8%) 34 (20.2%)$ 10 (20.4%)*
Enterobacter 53 (5.5%) 13 (7.7%) 1 (2.0%)
Klebsiella 60 (6.2%) 11 (6.5%) 0
Proteus 39 (4.0%) 9 (5.3%) 1 (2.0%)
Acinetobacter 37 (3.8%) 3 (1.7%) 2 (4.0%)
Haemophilus 33 (2.4%) 3 (1.8%) 1 (2.0%)
Fungi
Candida albicans 125 (13%) 28 (16.7%) 3 (6.1%)
Candida non-albicans 37 (3.9%) 9 (5.4%) 3 (6.1%)
Other fungi 13 (1.3%) 3 (1.7%) 1 (2.0%)
MRSA: methicillin-resistant Staphylococcus aureus. *p < 0.05 versus no-cancer group; $ p < 0.001 versus no-cancer group. Data are presented 
as number (percentage).Critical Care    Vol 13 No 1    Taccone et al.
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Outcome
ICU (20% versus 18%) and hospital (27% versus 23%) mor-
tality rates were similar in patients with solid tumours and
those without cancer, respectively, but medical patients had a
higher hospital mortality rate than surgical patients (41% ver-
sus 21%; p < 0.001). However in multivariable analysis, surgi-
cal status was not an independent predictor of mortality in
patients with solid cancers. Patients with haematological can-
cer had higher ICU (42% versus 18%) and hospital (58% ver-
sus 23%) mortality rates than non-cancer patients (both p <
0.001) (Figure 2). The same pattern was present when only
the patients with sepsis were analysed in the three groups
(Figure 3).
In a multivariable analysis, in the patients with solid tumours,
SAPS II score, sepsis, ALI/ARDS and mechanical ventilation
were associated with increased hospital mortality (Table 4). In
patients with haematological cancer, SAPS II score and ALI/
ARDS were associated with increased hospital mortality
(Table 5).
Discussion
This study showed that 15% of patients admitted to European
ICUs have cancer (mostly solid tumours). Previous studies
described only oncological patients in specialised ICUs [4-6]
or were based on retrospective analyses of patients admitted
to a single centre without comparison with a non-cancer pop-
ulation [1,10,22]. Analysis of a large US database of more
than seven million adult hospital admissions showed that only
9% of admissions were associated with a diagnosis of cancer
[23]; however, no specific data were presented on ICU admis-
sions. Overall in our study, the outcome of patients with solid
cancer was comparable with that of the general ICU popula-
tion, with a 27% hospital mortality rate. However, in patients
with more than three organs failing, more than 75% of those
with cancer died compared with 50% of patients without can-
cer.
We report our results separately for patients with solid and
haematological malignancies as these populations are quite
different [10]. Patients with haematological cancers were
more severely ill and more commonly had sepsis than patients
without cancer, resulting in the highest ICU and hospital mor-
tality rates. The poor prognosis of patients with haematological
malignancies who require ICU admission has been well docu-
mented, with global hospital mortality rates of 45 to 55%
[22,24], increasing to 72% when mechanical ventilation is
required [25]. However, recent reports have stressed that
aggressive treatment of critical illness events, as well as start-
ing chemotherapy in the ICU for a life-threatening malignancy-
related complication, can be lifesaving even when infection or
organ failure is present [26].
In contrast, patients with solid tumours had similar severity
scores and general profiles to the non-cancer population; they
were somewhat older and more commonly had sepsis, factors
associated with a worse outcome, but they were more com-
monly surgical admissions, a factor generally associated with
a better outcome than medical admissions [27].
The ICU mortality rate for cancer patients in our study is lower
than that previously reported [28]; however, a direct compari-
son is difficult because of the lack of data on the origin of can-
cer in our study and the possibility that less 'aggressive'
malignancies could have been included. More recent papers
have reported ICU mortality rates of 40 to 69% [22,24,29,30];
a lower mortality rate of just 10% was reported in one study
but half of the patients were admitted for uncomplicated mon-
itoring [31].
The intensity of treatment was the same in cancer patients as
in the general population, as shown by the similar use of
mechanical ventilation, vasoactive agents and haemofiltration.
Figure 1
Organ dysfunction Organ dysfunction. Maximum number of organ dysfunctions during the 
intensive care unit (ICU) stay (upper panel) and hospital mortality 
according to the number of organ dysfunctions (lower panel) in the 
three groups of patients. White bars = no cancer; gray bars = haema-
tological cancer; black bars = solid tumours.Available online http://ccforum.com/content/13/1/R15
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Table 3
Respiratory and haematological dysfunction, ICU monitoring and treatment
No cancer
(n = 2674)
Solid tumours
(n = 404)
Haematological cancer
(n = 69)
Mechanical ventilation 1724 (64.5%) 253 (62.6%) 48 (69.6%)
ALI/ARDS 325 (12.2%) 47 (11.6%) 21 (30.4%)$
PaO2/FiO2 202.8 (133.4 to 295.0) 224.0 (144.0 to 324.3) 140.0 (94.0 to 206.2)$
MV, days/patient 3.0 (1.0 to 7.0) 2.0 (1.0 to 6.0) 4.0 (2.0 to 6.0)
Leucopenia 43 (1.6%) 14 (3.5%)* 17 (24.6%)$
Thrombocytopenia 373 (13.9%) 52 (12.9%) 35 (50.7%)$
Pulmonary artery catheter 430 (16.1%) 37 (9.2%)$ 14 (20.3%)
Central venous catheter 1896 (70.9%) 317 (78.5%) 59 (85.5%)
Arterial catheter 1882 (70.4%) 304 (75.2%) 54 (78.3%)$
Vasopressors 1089 (40.7%) 163 (40.3%) 41 (59.4%)*
Inotropes 505 (18.9%) 61 (15.1%) 20 (29.0%)*
Haemofiltration 184 (6.9%) 16 (4.0%) 11 (15.9%)*
Haemodialysis 121 (4.5%) 16 (4.0%) 4 (5.8%)
ALI: acute lung injury; ARDS: acute respiratory distress syndrome; FiO2: inspired fraction of oxygen; ICU = intensive care unit; MV: mechanical 
ventilation; PaO2: arterial partial pressure of oxygen.
* p < 0.05 versus no-cancer group; $ p < 0.001 versus no-cancer group.
Data are presented as number (percentage) or median (interquartile range)
Figure 2
Kaplan Meier 60-day survival curves of the three groups of patients Kaplan Meier 60-day survival curves of the three groups of patients. 
Log Rank score = 20.78; p < 0.01.
Figure 3
Hospital mortality in the three groups of patients overall and in patients  with sepsis Hospital mortality in the three groups of patients overall and in patients 
with sepsis. White bars = no cancer; gray bars = haematological can-
cer; black bars = solid tumours. *p < 0.001 versus no-cancer group.Critical Care    Vol 13 No 1    Taccone et al.
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Patients with solid tumours were less likely to be monitored
with a pulmonary artery catheter, and this was not explained by
the differences in heart surgery or by the higher frequency of
cardiac failure.
Sepsis is one of the major causes of ICU admission for cancer
patients and is an important cause of hospital mortality and
morbidity. Cancer has been reported in about 17% of medical
admissions associated with sepsis [18,32], with a higher inci-
dence in patients with haematological cancer, probably
because of associated leucopenia [33]. Indeed, infection was
the main cause of admission for these patients (52%) in our
study with a predominance of respiratory infections, as
reported previously [17,34,35]. Apart from a higher incidence
of  E. coli and abdominal infections in patients with solid
tumours than in non-cancer patients (which could not be
explained by the larger number of surgical admissions in solid
tumour patients or by the incidence of surgical wound infec-
tions), we found a similar spectrum of micro-organisms in
patients with and those without cancer. This was even true for
infections due to Candida species, which are usually more
common in leucopenic cancer patients [36]. ICU-acquired
infection rates were also comparable. These observations
suggest that these patients can be treated with the same anti-
biotic protocols as other ICU patients if there is no febrile neu-
tropenia.
A multivariable analysis identified a higher severity score and
the presence of ALI/ARDS as independent prognostic factors
for hospital mortality in patients with haematological cancers,
and a higher SAPS II score, mechanical ventilation, presence
of sepsis and presence of ALI/ARDS in solid cancer patients.
Acute physiology and chronic health evaluation (APACHE) II
[37] and SAPS II [38] scores have been specifically validated
in certain groups of critically ill cancer patients. The SOFA
score also has good prognostic value in critical haemato-
oncological disease, suggesting that outcome for ICU cancer
patients is determined primarily by the organ dysfunctions
induced by complications rather than by the stage of the
underlying malignancy [12,39,40]. Our study confirms that
survival is dependent on the number of organ failures and that
respiratory insufficiency, especially when mechanical ventila-
tion is required [13,41-43], is associated with the highest risk
of death.
A limitation of our study, which was not focused specifically on
cancer patients, is that we had no specific information about
the characteristics of the cancer, including type, stage, histo-
logical findings, anticancer treatments or performance status.
The defined groups of 'solid' and 'haematological' cancers
encompass different diseases with different biological behav-
iours and severities, thus we could not correlate mortality to
these characteristics. However, in the ICU setting, the physio-
logical changes induced by the acute illness may represent
the major determinant for the outcome of patients, more than
cancer-related characteristics [4]. In addition, the group of
cancer patients with more than three organs failing was small
and conclusions on the influence of organ dysfunction on mor-
tality should be made with caution. Finally, decisions to limit
therapy, and particularly 'do not resuscitate' orders, were not
recorded.
Conclusions
The interesting aspect of our study was the inclusion of con-
secutive admissions of cancer and non-cancer patients during
the same, albeit limited, time period. This study can be seen as
an audit of clinical practice in Europe concerning the admis-
sion of patients with cancer to the ICU, the intensity of treat-
ment and the types of complications. Thus, our results have
ethical implications. Malignancies are becoming increasingly
common, especially as the population ages, and cancer
patients are likely to represent an increasing proportion of ICU
populations. As the mortality rate in patients with cancer in our
study was similar to that reported in recent studies and cancer
patients underwent complete resuscitation and monitoring,
our observations suggest that patients with a poor functional
status or refractory malignancy are not being admitted to the
ICU; treatment of critical complications resulted in acceptable
rates of ICU mortality, without evidence of futile therapy. Simi-
Table 4
Prognostic factors for hospital mortality by multivariate 
forward stepwise logistic regression analysis in patients with 
solid cancer (n = 404)
OR 95% CI p value
SAPS II* 1.07 1.05 to 1.08 <0.001
Sepsis 2.1 1.2 to 3.7 0.01
ALI/ARDS 2.5 1.2 to 5.3 0.014
Mechanical ventilation 2.4 1.2 to 4.7 0.015
ALI = acute lung injury; ARDS = acute respiratory distress 
syndrome; CI = confidence interval; OR = odds ratio; SAPS = 
simplified acute physiology score. *on admission.
Hosmer and Lemeshow goodness-of-fit test chi-squared = 10.15 (p 
= 0.26). This model has a 79.5% correct classification (50.9% for 
non-survivors and 90.3% for survivors).
Table 5
Prognostic factors for hospital mortality by multivariate 
forward stepwise logistic regression analysis in patients with 
haematological cancer (n = 69)
OR 95% CI p value
SAPS II* 1.07 1.0. to 1.2 0.002
ALI/ARDS 5.3 1.4 to 20.4 0.015
ALI = acute lung injury; ARDS = acute respiratory distress 
syndrome; CI = confidence interval; OR = odds ratio; SAPS = 
simplified acute physiology score. *on admission.
Hosmer and Lemshow goodness-of-fit test chi-squared = 15.53 (p = 
0.1). This model has a 75.4% correct classification (80.0% for non-
survivors and 69.0% for survivors).Available online http://ccforum.com/content/13/1/R15
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lar to previous observations [3,13,38], our study emphasises
that ICU admission should not be denied only on the basis of
a patient having a neoplastic disease.
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